BeiGene, Ltd.
06160
2023 6 30
13.09
571 XIVA
2023 6 30
2023 6 30
2023
2023 8 2
2023 8 31 2023 6 30
1995 (Private Securities Litigation
Reform Act of 1995) 悅
1
BTK
2023
10-Q
2023 8 2
Margaret Han Dugan Donald W. Glazer
Michael Goller Anthony C. Hooper Ranjeev Krishana Thomas
Malley Alessandro Riva Corazon (Corsee) D. Sanders
2
2023
5.54
82%
3.08 139% 46%
(CLL)
BTK
BGNE
06160 688235
2023
(John V. Oyler)
CLL
(R/R)CLL
BTK
(EMA) (CHMP)
(ESCC)
(FDA)
(sNDA)
R/R (FL)
FDA 2024
3
CLL
(TGA)
(TN) R/R CLL
(SLL)
(NMPA)
sNDA TN CLL/SLL (WM)
R/R CLL/SLL R/R
WM
http://ir.beigene.com; https://hkexir.beigene.com; https://sseir.beigene.com
(ADC)
ADC
Max 29
CLL
Max
2023
2023 6 30 5.537
81.8% 2022 3.045
2023 2.492
2023
2.235
152.9% CLL/SLL
FDA
4,850 32.2%
BTK
4
2023
1.495
42.5%
PD-1
6 30 6 30
2023 2022 2023 2022
$ $ $ $
293,919 212,429 540,828 403,164
223,540 88,381 362,307 156,269
36,286 3,701 60,901 6,651
553,745 304,511 964,036 566,084
2023 82.7%
76.6%
2023 6 30 8.18
2022 7.098 15.2%
81.8%
2023 6 30 3.811
0.28 (ADS) 3.64 2022
5.657 0.42 ADS 5.50
2023 6,380
2022 1.296
2023 6 30 35
2022 12 31 45
2023
2023 10-Q
5
CLL/SLL
TN R/R CLL/SLL
NMPA
o
TN CLL/SLL
o
TN WM
o
R/R CLL/SLL
o
R/R WM
EMA CHMP
ESCC
NMPA
o
PD-L1
o ESCC
NMPA
R/R FL sNDA
FDA
R/R FL
(MAA) EMA
3
6
*
ESCC
(ES-SCLC)
ESCC
ESCC
R/R
CLL 3 ALPINE
(NSCLC) 3
RATIONALE-315
Sonrotoclax 2023
BCL-2
CLL
BGB-11417
2023 R/R
WM
1
BTK CDAC B 1
(BGB-16673)
2023 NSCLC
TIGIT 3 AdvanTIG-302
2
o PD-
(L)1 ESCC
o (HCC)
o NSCLC
* PDUFA
7
9 2023
3 RATIONALE-312
10 (ESMO) 8
(ASCO) (EHA)
R/R B (DLBCL) 1
R/R FL 3 ROSEWOOD
ASCO
3 RATIONALE 301
(HCC)
ASCO OX40 BGB-A445 1
Zymeworks ASCO zanidatamab
HER2 2b HERIZON-BTC
7 100
9.3
2024
64,000
(ADC) 2024
55.9 5.2
6 2023
5
2024
8
TIGIT
9
2023 2022
6 30 12 31
$ 3,527,267 $ 4,540,288
299,282 173,168
321,333 282,346
1,031,938 845,946
5,728,736 6,379,290
266,975 294,781
454,950 467,352
183,310 255,887
271,291 293,960
628,478 538,117
1,930,177 1,995,935
$ 3,798,559 $ 4,383,355
10
ADS ADS
6 30 6 30
2023 2022 1
2023 2022 1
$ 553,745 $ 304,511 $ 964,036 $ 566,084
41,516 37,061 79,026 82,114
595,261 341,572 1,043,062 648,198
95,990 71,173 177,779 136,410
422,764 378,207 831,348 768,122
395,034 331,403 723,533 625,976
188 188 375 376
913,976 780,971 1,733,035 1,530,884
(318,715) (439,399) (689,973) (882,686)
15,070 11,431 31,086 21,502
(63,818) (129,617) (45,515) (117,650)
(367,463) (557,585) (704,402) (978,834)
13,674 8,141 25,166 22,090
(381,137) (565,726) (729,568) (1,000,924)
$ (0.28) $ (0.42) $ (0.54) $ (0.75)
1,360,224,377 1,336,463,026 1,357,211,308 1,334,252,648
ADS
$ (3.64) $ (5.50) $ (6.99) $ (9.75)
ADS
104,632,644 102,804,848 104,400,870 102,634,819
1
2022 2023
6 30 10-Q 1.
2.
11
10,000
www.beigene.com.cn
1995 (Private Securities Litigation
Reform Act of 1995)
BTK
2023
10-Q
(+86 10)5895-8058 (+86 10)6844-5311
ir@beigene.com media@beigene.com
(Genentech, Inc.)
Pharmacyclics LLC
12